Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 20, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis.

Tomoya Hatayama1, Yohei Sekino1, Go Kobayashi2

  • 1Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

Clinical Genitourinary Cancer
|May 18, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

System-Level Analysis of Japan's Pediatric-Perinatal Disaster Liaison Operations During the 2024 Noto Earthquake.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

Engineered hepatic cells with stable expansion and heat-inducible liver function.

Scientific reports·2026
Same author

Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma.

Scientific reports·2026
Same author

Incidence and Risk Factors for Perioperative Infections After Robot-Assisted Radical Prostatectomy: A Multicenter Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Bone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma.

Cancers·2026
Same author

Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.

International journal of urology : official journal of the Japanese Urological Association·2026

Tumor mutational burden (TMB) in prostate cancer (PCa) correlates with aggressiveness and prior treatments. High TMB indicates poorer survival, but combining TMB with microsatellite instability (MSI) may improve immunotherapy predictions.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biomarkers

Background:

  • Tumor mutational burden (TMB) predicts immune checkpoint inhibitor (ICI) response.
  • Prostate cancer (PCa) TMB mechanisms and prognostic value are unclear.
  • Investigating TMB associations in PCa is crucial for treatment strategies.

Purpose of the Study:

  • To analyze associations between TMB and clinicopathological, genomic, and treatment factors in PCa.
  • To evaluate the prognostic utility of TMB across different PCa treatment regimens.
  • To explore TMB's role in predicting response to immune checkpoint inhibitors (ICIs) in PCa.

Main Methods:

  • Retrospective analysis of clinicopathological, genomic, and survival data from four PCa studies.
  • Statistical analyses including Wilcoxon rank-sum, log-rank tests, and logistic regression.
Keywords:
BiomarkerGenomic mutationOncoplotPublic data analysisTreatment pressure

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: May 20, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

  • TMB stratification using cut-offs of 5 or 10 mutations/Mb; oncoplot analyses performed.

    • Main Results:

    • Higher TMB associated with aggressive PCa features and prior therapies (hormone, taxane).
    • TMB-high/intermediate (≥5 mutations/Mb) linked to poorer overall survival (OS) in overall and hormone therapy cohorts.
    • TMB alone did not reliably predict ICI outcomes; combined TMB and MSI showed borderline improved OS in ICI-treated patients.

    Conclusions:

    • TMB in PCa is influenced by tumor aggressiveness and treatment-induced mutations.
    • Combined TMB and microsatellite instability (MSI) assessment may improve immunotherapy stratification and prognostication in PCa.
    • Further research needed to elucidate TMB's role in PCa treatment response.